ENTA
Enanta Pharmaceuticals Inc (ENTA)
Healthcare • NASDAQ • $13.72-2.42%
- Symbol
- ENTA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $13.72
- Daily Change
- -2.42%
- Market Cap
- $368.13M
- Trailing P/E
- N/A
- Forward P/E
- -6.48
- 52W High
- $17.15
- 52W Low
- $6.44
- Analyst Target
- $20.14
- Dividend Yield
- N/A
- Beta
- 0.99
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Labo…
Company websiteResearch ENTA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.